Immune responses to adeno-associated virus and its recombinant vectors
暂无分享,去创建一个
S. Chatterjee | K. Wong | J Y Sun | V Anand-Jawa | S Chatterjee | K K Jr Wong | J. Sun | Kk Wong | JY Sun | V. Anand-Jawa
[1] J. Bennett,et al. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] S. Forman,et al. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. , 1996, Blood.
[3] T. Reynolds,et al. T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.
[4] J. Escobedo,et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. , 1998, Human gene therapy.
[5] P. Fan,et al. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. , 1996, Human gene therapy.
[6] K. Propert,et al. Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.
[7] J. Lipski,et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. , 2000, Science.
[8] S. Kung,et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. , 1998, Blood.
[9] R. Samulski,et al. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. , 1999, Nature medicine.
[10] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[11] S. Ponnazhagan,et al. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation , 1997, Journal of virology.
[12] H. Sweeney,et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. , 2001, Human gene therapy.
[13] O. Danos,et al. Successful Interference with Cellular Immune Responses to Immunogenic Proteins Encoded by Recombinant Viral Vectors , 2001, Journal of Virology.
[14] W. Rascher,et al. Sustained delivery of therapeutic concentrations of human clotting factor IX – a comparison of adenoviral and AAV vectors administered in utero , 2002, The journal of gene medicine.
[15] R. Heilbronn,et al. Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. , 1998, Journal of virological methods.
[16] D. Russell,et al. Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2 , 1998, Journal of Virology.
[17] T. Kezuka,et al. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation. , 2000, Investigative ophthalmology & visual science.
[18] J. Bennett,et al. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. , 2000, Human gene therapy.
[19] I. Verma,et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] P. Beard,et al. Virus-mediated killing of cells that lack p53 activity , 2001, Nature.
[21] M. Kay,et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.
[22] I. Martins,et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] Keyun Qing,et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 , 1999, Nature Medicine.
[24] James M. Wilson,et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Batshaw,et al. Humoral Immune Response to Recombinant Adenovirus and Adeno-Associated Virus after In Utero Administration of Viral Vectors in Mice , 2002, Pediatric Research.
[26] Jody A. Vandergriff,et al. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38− subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV , 2000, Gene Therapy.
[27] M. Hoggan,et al. Serologic evidence for human infection with adenovirus-associated viruses. , 1968, Journal of the National Cancer Institute.
[28] A. Bruce,et al. Sustained expression of human factor VIII in mice using a parvovirus-based vector. , 2000, Blood.
[29] F. Marincola,et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Schlehofer,et al. Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.
[31] R. Herzog,et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.
[32] S. Chatterjee,et al. Adeno-associated virus based vectors as antivirals. , 1996, Current topics in microbiology and immunology.
[33] C. Walsh,et al. Induction of tolerance to human factor VIII in mice. , 2001, Blood.
[34] D. Mohuczy,et al. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension. , 1999, American journal of physiology. Heart and circulatory physiology.
[35] R. Herzog,et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] Lili Wang,et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[37] James M. Wilson,et al. Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.
[38] M. Rocchi,et al. Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[39] S. Takeda,et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product , 2002, Gene Therapy.
[40] R. Brady,et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] M. Dunckley,et al. Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors , 1998, Gene Therapy.
[42] G. Deléage,et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.
[43] A. Nienhuis,et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. , 2001, Blood.
[44] B. Byrne,et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.
[45] Philip R. Johnson,et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. , 1999, Human gene therapy.
[46] P. Hermonat,et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector , 2001, Cancer Gene Therapy.
[47] A. Beaudet,et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. , 1999, Human gene therapy.
[48] G. Dickson,et al. Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review). , 2000, International journal of molecular medicine.
[49] James M. Allen,et al. Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes , 2000, Journal of Virology.
[50] C. Contag,et al. In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] P. Hermonat,et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno‐associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells , 2002, European journal of immunology.
[52] N. Wong,et al. Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors , 2002, Journal of Virology.
[53] James M. Wilson,et al. Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.
[54] C. Halbert,et al. Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.
[55] Y. Tsao,et al. Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer , 2000, Journal of Virology.
[56] J. Bartlett,et al. Gene therapy: Recombinant adeno-associated virus vectors , 2001, Current cardiology reports.
[57] T. Flotte,et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[58] H. Mizukami,et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. , 2001, Human gene therapy.
[59] B. Byrne,et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.
[60] A. Gown,et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.
[61] P. Hermonat,et al. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. , 2000, Virology.
[62] E. Engleman,et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. , 1999, Clinical immunology.
[63] A. Gown,et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[64] R. Samulski,et al. αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection , 1999, Nature Medicine.
[65] J. Schlehofer,et al. The tumor suppressive properties of adeno-associated viruses. , 1994, Mutation research.
[66] T. Flotte,et al. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. , 1996, Human gene therapy.
[67] P. Billings. In utero gene therapy: The case against , 1999, Nature Medicine.
[68] H. zur Hausen,et al. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. , 1984, Virology.
[69] R. Samulski,et al. Adeno-associated viral vectors as gene delivery vehicles. , 2000, International journal of molecular medicine.
[70] R. Herzog,et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[71] N. Chirmule,et al. CD40 Ligand-Dependent Activation of Cytotoxic T Lymphocytes by Adeno-Associated Virus Vectors In Vivo: Role of Immature Dendritic Cells , 2000, Journal of Virology.
[72] C. Walker,et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D , 1997, Journal of virology.
[73] T. Flotte,et al. Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.
[74] J. Mcarthur,et al. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. , 2001, Blood.
[75] R. Herzog,et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.
[76] R. Samulski,et al. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.
[77] J. Kaplan,et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. , 1997, Gene.
[78] R. Samulski,et al. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[79] P. Laipis,et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.
[80] M. Hallek,et al. Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2–Cell Interaction and Neutralization of AAV-2 Infection , 2000, Journal of Virology.
[81] O. Danos,et al. Factors influencing cross‐presentation of non‐self antigens expressed from recombinant adeno‐associated virus vectors , 2001, The journal of gene medicine.
[82] R. Chanock,et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. , 1971, American journal of epidemiology.
[83] B. Williams,et al. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. , 1997, Experimental hematology.
[84] A. Srivastava,et al. Adeno-associated Virus 2-Mediated Transduction and Erythroid Lineage-Restricted Long-Term Expression of the Human β-Globin Gene in Hematopoietic Cells from Homozygous β-Thalassemic Mice , 2001 .
[85] R. Samulski,et al. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.
[86] James M. Wilson,et al. Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.
[87] J. Wilson,et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[88] De-Pei Liu,et al. Hot topics in adeno-associated virus as a gene transfer vector , 2001, Molecular biotechnology.
[89] J. Mcarthur,et al. Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure , 2000, Journal of Virology.
[90] R. Samulski,et al. Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.
[91] T. Griffith,et al. The immune response and the eye. TCR alpha-chain related molecules regulate the systemic immunity to antigen presented in the eye. , 1995, International immunology.
[92] J. Bartlett,et al. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. , 2001, Human gene therapy.
[93] T. Flotte,et al. Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway , 1999, Journal of Virology.
[94] K. Qing,et al. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[95] J. Rosenblatt,et al. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes , 1994, Molecular and cellular biology.
[96] S. Forman,et al. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. , 2002, Cancer research.
[97] G. Deléage,et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.
[98] G. Podsakoff,et al. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors , 1994, Journal of virology.
[99] Wei Li,et al. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. , 1999, Blood.
[100] K. High,et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice , 2001, Gene Therapy.
[101] H. Ertl,et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[102] G. Stamatoyannopoulos,et al. A High-Capacity, Capsid-Modified Hybrid Adenovirus/Adeno-Associated Virus Vector for Stable Transduction of Human Hematopoietic Cells , 2002, Journal of Virology.
[103] Katherine A. High,et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.
[104] Lili Wang,et al. Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer , 2001, Journal of Virology.
[105] J. Kleinschmidt,et al. Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins , 1997, Journal of virology.
[106] F. Wolber,et al. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. , 2002, Blood.
[107] James M. Wilson,et al. Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.
[108] C. Giraud,et al. Biology of adeno-associated virus. , 1996, Current topics in microbiology and immunology.
[109] M. S. Chapman,et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.